269 related articles for article (PubMed ID: 37512096)
21. Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer.
Gao J; Zhao Z; Zhang H; Huang S; Xu M; Pan H
Cancer Immunol Immunother; 2023 May; 72(5):1121-1138. PubMed ID: 36336725
[TBL] [Abstract][Full Text] [Related]
22. Immunity and Extracellular Matrix Characteristics of Breast Cancer Subtypes Based on Identification by T Helper Cells Profiling.
Zhou Y; Tian Q; Gao H; Zhu L; Zhang Y; Zhang C; Yang J; Wang B
Front Immunol; 2022; 13():859581. PubMed ID: 35795662
[TBL] [Abstract][Full Text] [Related]
23. Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2/AKT/β-catenin signaling.
Chen X; Yang M; Yin J; Li P; Zeng S; Zheng G; He Z; Liu H; Wang Q; Zhang F; Chen D
Cell Commun Signal; 2022 Jun; 20(1):92. PubMed ID: 35715860
[TBL] [Abstract][Full Text] [Related]
24. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.
Zhou Y; Che Y; Fu Z; Zhang H; Wu H
Front Public Health; 2022; 10():902378. PubMed ID: 35875026
[TBL] [Abstract][Full Text] [Related]
25. Tumor microenvironment characterization in triple-negative breast cancer identifies prognostic gene signature.
Qin Y; Deng J; Zhang L; Yuan J; Yang H; Li Q
Aging (Albany NY); 2021 Feb; 13(4):5485-5505. PubMed ID: 33536349
[TBL] [Abstract][Full Text] [Related]
26. Development of an ubiquitin-proteasome system signature for predicting prognosis and providing therapeutic guidance for patients with triple-negative breast cancer.
Chen X; Ren C; Zhou Z; Chen J; Fan X; Li X; Chen J; Zhu J
J Gene Med; 2024 Jan; 26(1):e3584. PubMed ID: 37605934
[TBL] [Abstract][Full Text] [Related]
27. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
28. Development and verification of a novel immunogenic cell death-related signature for predicting the prognosis and immune infiltration in triple-negative breast cancer.
Li J; Li Z; Yang W; Pan J; You H; Yang L; Zhang X
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2007. PubMed ID: 38425247
[TBL] [Abstract][Full Text] [Related]
29. Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer.
Chen X; Li Z; Liang M; Zhang Z; Zhu D; Lin B; Zhou R; Lu Y
World J Surg Oncol; 2023 Jun; 21(1):194. PubMed ID: 37391802
[TBL] [Abstract][Full Text] [Related]
30. Single-cell and bulk RNA sequencing analysis of B cell marker genes in TNBC TME landscape and immunotherapy.
Zhao F; Zhao C; Xu T; Lan Y; Lin H; Wu X; Li X
Front Immunol; 2023; 14():1245514. PubMed ID: 38111587
[TBL] [Abstract][Full Text] [Related]
31. A CTL/M2 macrophage-related four-gene signature predicting metastasis-free survival in triple-negative breast cancer treated with adjuvant radiotherapy.
Ye Y; Ma J; Zhang Q; Xiong K; Zhang Z; Chen C; Xiao H; Wang D
Breast Cancer Res Treat; 2021 Nov; 190(2):329-341. PubMed ID: 34482483
[TBL] [Abstract][Full Text] [Related]
32. The molecular subtypes of triple negative breast cancer were defined and a ligand-receptor pair score model was constructed by comprehensive analysis of ligand-receptor pairs.
Pan W; Song K; Zhang Y; Yang C; Zhang Y; Ji F; Zhang J; Shi J; Wang K
Front Immunol; 2022; 13():982486. PubMed ID: 36119101
[TBL] [Abstract][Full Text] [Related]
33. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents.
Santoni M; Romagnoli E; Saladino T; Foghini L; Guarino S; Capponi M; Giannini M; Cognigni PD; Ferrara G; Battelli N
Biochim Biophys Acta Rev Cancer; 2018 Jan; 1869(1):78-84. PubMed ID: 29126881
[TBL] [Abstract][Full Text] [Related]
34. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
35. The GRP94 Inhibitor PU-WS13 Decreases M2-like Macrophages in Murine TNBC Tumors: A Pharmaco-Imaging Study with
Bouchard A; Sikner H; Baverel V; Garnier AR; Monterrat M; Moreau M; Limagne E; Garrido C; Kohli E; Collin B; Bellaye PS
Cells; 2021 Dec; 10(12):. PubMed ID: 34943901
[TBL] [Abstract][Full Text] [Related]
36. 3D Collagen Fiber Concentration Regulates Treg Cell Infiltration in Triple Negative Breast Cancer.
Gao H; Tian Q; Zhou Y; Zhu L; Lu Y; Ma Y; Feng J; Jiang Y; Wang B
Front Immunol; 2022; 13():904418. PubMed ID: 35774776
[TBL] [Abstract][Full Text] [Related]
37. An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer.
Li XF; Fu WF; Zhang J; Song CG
BMC Cancer; 2022 Jun; 22(1):619. PubMed ID: 35668369
[TBL] [Abstract][Full Text] [Related]
38. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
39. Integrated multi-cohorts for characterizing the immunogenomic landscape and predicting drug response in triple-negative breast cancer.
Su D; Chi M; Wang S; Di S; Zhang H; Lu Q; Yu Y; Xiong Y; Wei H; Lv Y; Zuo Y; Yang L
Brief Funct Genomics; 2022 May; 21(3):188-201. PubMed ID: 35348574
[TBL] [Abstract][Full Text] [Related]
40. High Throughput Transcriptome Data Analysis and Computational Verification Reveal Immunotherapy Biomarkers of Compound Kushen Injection for Treating Triple-Negative Breast Cancer.
Liu X; Wu Y; Zhang Y; Bu D; Wu C; Lu S; Huang Z; Song Y; Zhao Y; Guo F; Ye P; Fu C; Shen L; Zhang J; Wang H; Duan X; Wu J
Front Oncol; 2021; 11():747300. PubMed ID: 34604090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
